{"id":"i-t-morphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL5665374","moleculeType":null,"molecularWeight":"285.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Morphine is a mu-opioid receptor agonist that crosses the blood-brain barrier when administered intrathecally (I/T), allowing direct action on spinal cord opioid receptors to block pain signal transmission. This route of administration provides potent analgesia at lower systemic doses compared to oral or intravenous routes, reducing systemic side effects while achieving high local concentrations at the site of pain processing.","oneSentence":"Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia and sedation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:49.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain management via intrathecal delivery"},{"name":"Cancer pain"},{"name":"Post-operative pain"}]},"trialDetails":[{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT04470050","phase":"PHASE1, PHASE2","title":"Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2020-06-09","conditions":"Opioid Withdrawal","enrollment":225},{"nctId":"NCT05420337","phase":"NA","title":"Analgesic Effect of Morphine Added to Transverses Abdominis Plane Block","status":"COMPLETED","sponsor":"Eskisehir Osmangazi University","startDate":"2022-08-24","conditions":"Pain, Postoperative, Postoperative Complications","enrollment":52},{"nctId":"NCT00726830","phase":"NA","title":"Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03","conditions":"Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia","enrollment":1},{"nctId":"NCT01281891","phase":"PHASE4","title":"Postoperative Pain Relief Following Total Hip Arthroplasty. A Comparison Between Intrathecal Morphine (IM) and Local Infiltration Analgesia (LIA)","status":"UNKNOWN","sponsor":"Region Örebro County","startDate":"2009-09","conditions":"Primary Osteoarthritis Requiring Total Hip Replacement","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":141,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"I/T morphine","genericName":"I/T morphine","companyName":"Region Örebro County","companyId":"region-rebro-county","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Morphine binds to opioid receptors in the central and peripheral nervous system to produce analgesia and sedation. Used for Chronic pain management via intrathecal delivery, Cancer pain, Post-operative pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}